InvestSMART

PharmAust Limited (ASX: PAA) - Announcements

Current share price for PAA : $0.230 0.015 (6.98%)+

ASX company news and announcements for PharmAust Limited (PAA) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All PharmAust Limited (PAA) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than PharmAust Limited (PAA), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for PharmAust Limited (PAA)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Appendix 4C & Company Update - Sep 2018 1 Nov 2018 8:43AM $0.045 $0.230 risen by 411.11%
- PharmAust Develops GMP Method for Monepantel Analogues 29 Oct 2018 8:28AM $0.039 $0.230 risen by 489.74%
- PharmAust Progresses Monepantel Tablet Program for Cancer 15 Oct 2018 9:53AM $0.035 $0.230 risen by 557.14%
- Notice of Annual General Meeting/Proxy Form 10 Oct 2018 8:22AM $0.034 $0.230 risen by 576.47%
- Appendix 3X & 3Z 8 Oct 2018 6:48PM $0.037 $0.230 risen by 521.62%
- Neville Bassett AM appointed to PharmAust Board 2 Oct 2018 9:16AM $0.034 $0.230 risen by 576.47%
- Appendix 4G & Corporate Governance Statement 1 Oct 2018 8:51AM $0.035 $0.230 risen by 557.14%
- Annual Report 1 Oct 2018 8:50AM $0.035 $0.230 risen by 557.14%
- Olivia Newton-John Cancer Reseach Institute collaboration 10 Sep 2018 9:41AM $0.035 $0.230 risen by 557.14%
- Reformulation of MPL into tablet form for upcoming trials 4 Sep 2018 8:23AM $0.037 $0.230 risen by 521.62%
- Preliminary Final Report 3 Sep 2018 8:09AM $0.039 $0.230 risen by 489.74%
- Appendix 4C & Company Update - June 18 31 Jul 2018 6:17PM $0.037 $0.230 risen by 521.62%
- Epichem gains prestigious international ISO accreditation 2 Jul 2018 9:15AM n/a $0.230 n/a
- Becoming a substantial holder 29 Jun 2018 9:47AM $0.041 $0.230 risen by 460.98%
- Change of Director's Interest Notice - Bishop (re-release) 27 Jun 2018 10:29AM $0.042 $0.230 risen by 447.62%
- Change of Director's Interest Notice - Bishop 27 Jun 2018 8:22AM $0.041 $0.230 risen by 460.98%
- Change of Director's Interest Notice - Wright 26 Jun 2018 10:53AM $0.040 $0.230 risen by 475%
- Epichem Awarded Major US Drug Discovery Contract Extension 7 Jun 2018 9:10AM $0.045 $0.230 risen by 411.11%
- MPL successfully reformulated for canine clinical trials 28 May 2018 9:14AM $0.048 $0.230 risen by 379.17%
- Chief Executive Officer resigns 21 May 2018 6:15PM $0.049 $0.230 risen by 369.39%
- Appendix 4C & Company Update 1 May 2018 8:54AM $0.050 $0.230 risen by 360%
- PharmAust enters option to license agreement with Elanco 18 Apr 2018 9:53AM $0.051 $0.230 risen by 350.98%
- Trading Halt 16 Apr 2018 9:55AM $0.051 $0.230 risen by 350.98%
- Wayne Best appointed Epichem Chairman and Dr Keenan as CEO 10 Apr 2018 10:47AM $0.054 $0.230 risen by 325.93%
- Cleansing Notice 20 Mar 2018 7:39PM $0.056 $0.230 risen by 310.71%

451 - 475 of 796 results

Page 19 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.